EUVIMEDEUVIMED entdecken
Open Access

Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project

Shari S Rogal, Tamar H Taddei, Alexander Monto, Vera Yakovchenko, Heather Patton, Monica Merante, Patrick Spoutz, Linda Chia, Jennifer Yudkevich, Ayse Aytaman, Atoosa Rabiee, Binu V John und 12 weitere

Clinical Gastroenterology and Hepatology · 2024

DOI: 10.1016/j.cgh.2023.07.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Shari S Rogal und 23 weiteren Autor:innen. Beteiligte Einrichtung: VA Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania; Division of Gastroenterology, Hepatolo…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Veterans. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HSRD VA, NIDA NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: The coronavirus disease-2019 pandemic profoundly disrupted preventative health care services including cancer screening. As the largest provider of cirrhosis care in the United States, the Department of Veterans Affairs (VA) National Gastroenterology and Hepatology Program aimed to assess factors associated with hepatocellular carcinoma (HCC) stage at diagnosis, treatment, and survival. METHODS: Veterans with a new diagnosis of HCC in 2021 were identified from electronic health records (N = 2306). Structured medical record extraction was performed by expert reviewers in a 10% random subsample of Veterans with new HCC diagnoses. Factors associated with stage at diagnosis, receipt of treatment, and survival were assessed using multivariable models. RESULTS: Among 199 patients with confirmed HCC, the average age was 71 years and most (72%) had underlying cirrhosis. More than half (54%) were at an early stage (T1 or T2) at diagnosis. Less-advanced liver disease, number of imaging tests adequate for HCC screening, HCC diagnosis in the VA, and receipt of VA primary care were associated significantly with early stage diagnosis. HCC-directed treatments were administered to 145 (73%) patients after a median of 37 days (interquartile range, 19-54 d) from diagnosis, including 70 (35%) patients who received potentially curative treatments. Factors associated with potentially curative (vs no) treatments included HCC screening, early stage at diagnosis, and better performance status. Having fewer comorbidities and better performance status were associated significantly with noncurative (vs no) treatment. Early stage diagnosis, diagnosis in the VA system, and receipt of curative treatment were associated significantly with survival. CONCLUSIONS: These results highlight the importance of HCC screening and engagement in care for HCC diagnosis, treatment, and survival while demonstrating the feasibility of developing a national quality improvement agenda for HCC screening, diagnosis, and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsVeteransHumansUnited StatesAgedQuality ImprovementLiver CirrhosisRetrospective Studies

Stichwörter der Autor:innen

COVID-19CirrhosisLiver CancerVeterans

Autor:innen und Institutionen

  • VA Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, Pi…
  • VA Connecticut Healthcare System, West Haven, Connecticut; Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
  • San Francisco VA Health Care System, San Francisco, California.
  • VA Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
  • Gastroenterology Section, Jennifer Moreno VA San Diego Healthcare System, San Diego, California.
  • Pharmacy Benefits Management, Veterans Integrated Service Network 20, Vancouver, Washington.

Förderung

  • HSRD VA
  • NIDA NIH HHS
  • NCATS NIH HHS
  • Gilead Sciences
  • Government of South Australia
  • Exact Sciences Corporation
  • National Institutes of Health
  • National Institute on Drug Abuse

Zitieren

APA

Rogal, S. S., Taddei, T. H., Monto, A., Yakovchenko, V., Patton, H., Merante, M., Spoutz, P., Chia, L., Yudkevich, J., Aytaman, A., Rabiee, A., John, B. V., Blechacz, B., Cai, C. X., Gilles, H., Shah, A. S., McCurdy, H., Puri, P., Jou, J., …, & Ioannou, G. N. (2024). Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.07.002

Vancouver

Rogal SS, Taddei TH, Monto A, Yakovchenko V, Patton H, Merante M, et al. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.07.002

BibTeX
@article{Rogal2024,
  author = {Rogal, Shari S and Taddei, Tamar H and Monto, Alexander and Yakovchenko, Vera and Patton, Heather and Merante, Monica and Spoutz, Patrick and Chia, Linda and Yudkevich, Jennifer and Aytaman, Ayse and Rabiee, Atoosa and John, Binu V and Blechacz, Boris and Cai, Cindy X and Gilles, HoChong and Shah, Anand S and McCurdy, Heather and Puri, Puneet and Jou, Janice and Mazhar, Khurram and Dominitz, Jason A and Anwar, Jennifer and Morgan, Timothy R and Ioannou, George N},
  title = {Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1016/j.cgh.2023.07.002}
}
Kostenlos starten →